Loading…
Reported covered position: Law Clerk, Income Security and Family Support Subcmte, Ways and Means
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, AMP-Cap; Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; FY-2022 Budget and Appropriations Legislation.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MERCK & CO INC via MERCK & CO, INC.
2021 · first_quarter · Q1
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
Source: Senate LDA
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
Advancing Emergency Preparedness Through One Health Act of 2021
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
Pandemic Treatment Access and Affordability Act of 2021
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, AMP-Cap; Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; FY-2022 Budget and Appropriations Legislation.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, AMP-Cap; Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; FY-2022 Budget and Appropriations Legislation.
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, AMP-Cap; Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; FY-2022 Budget and Appropriations Legislation.
Medicare Negotiation and Competitive Licensing Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Medicare Negotiation and Competitive Licensing Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Medicare Negotiation and Competitive Licensing Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; Medicare Part B and D drug pricing issues; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing issues; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
Medicare Prescription Drug Price Negotiation Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Medicare Prescription Drug Price Negotiation Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Medicare Prescription Drug Price Negotiation Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
Protecting Seniors Through Immunization Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
Protecting Seniors Through Immunization Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
Community Immunity During COVID–19 Act of 2020
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
Community Immunity During COVID–19 Act of 2020
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; Medicare Part B and D drug pricing issues; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing issues; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations.
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
Prescription Drug Pricing Reduction Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; Medicare Part B and D drug pricing issues; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing issues; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Part D inflationary rebate, International pricing index, Drug Pricing and Center for Medicare & Medicaid Demonstrations.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
More Efficient Tools to Realize Information for Consumers Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, AMP-Cap; Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; FY-2022 Budget and Appropriations Legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2020 · fourth_quarter · Q4
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; Medicare Part B and D drug pricing issues; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing issues; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2020 · third_quarter · Q3
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2020 · second_quarter · Q2
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146)
Issues relating to, Intellectual Property; US-Mexico-Canada Agreement; US-China trade.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2020 · first_quarter · Q1
Issues relating to, Intellectual Property; US-Mexico-Canada Agreement; US-China trade.
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; Coronavirus Preparedness and response supplemental appropriations Act (P.L. 116-123); Families First Coronavirus Response Act (P.L. 116-127); Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-146).
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2019 · first_quarter · 1A
Intellectual property
Animal Health
Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Drug Pricing
MERCK & CO INC via MERCK & CO, INC.
2019 · fourth_quarter · 4A
Issues relating to, Intellectual Property; US-Mexico-Canada Agreement; US-China trade; Patents/IP; Market exclusivity.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
MERCK & CO INC via MERCK & CO, INC.
2019 · fourth_quarter · Q4
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
MERCK & CO INC via MERCK & CO, INC.
2019 · third_quarter · Q3
Intellectual Property, US-Mexico-Canada Agreement and US-China trade
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Part D inflationary rebate, International pricing index, Drug Pricing and Center for Medicare & Medicaid Demonstrations.
MERCK & CO INC via MERCK & CO, INC.
2019 · second_quarter · Q2
Intellectual Property, Intellectual Property Rebate Cap, Patents, US-Mexico-Canada Agreement and US-China trade
340B Reforms, Drug pricing, Anti-microbial Resistance, AMRDrug Pricing; General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Patent Thickets, W&M Markup Transparency, Biosimiliars, Diabetes, Cost and Value of Medicines, Maternal Health and Mortality, Women's Reproductive, Research and Development, Vaccines.
Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Drug Pricing and Center for Medicare & Medicaid Innovation.
MERCK & CO INC via MERCK & CO, INC.
2019 · first_quarter · Q1
Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Drug Pricing
Intellectual property
Tax Reform, Appropriations
Tax Reform, Appropriations
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues relating to, Intellectual Property; US-Mexico-Canada Agreement; US-China trade; Patents/IP; Market exclusivity.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Animal Health
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE